Aurinia Pharmaceuticals Inc.
AUPH
$15.35
$0.171.12%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 311.51M | 298.30M | 283.06M | 265.81M | 260.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 311.51M | 298.30M | 283.06M | 265.81M | 260.11M |
| Cost of Revenue | 81.32M | 77.24M | 77.58M | 65.14M | 62.98M |
| Gross Profit | 230.18M | 221.06M | 205.47M | 200.67M | 197.13M |
| SG&A Expenses | 100.97M | 103.48M | 101.79M | 109.57M | 125.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -19.80M | -4.32M | -170.00K | 16.00M | 19.64M |
| Total Operating Expenses | 151.06M | 163.99M | 166.79M | 184.70M | 197.00M |
| Operating Income | 160.45M | 134.30M | 116.26M | 81.10M | 63.11M |
| Income Before Tax | 160.36M | 133.73M | 114.16M | 79.64M | 62.49M |
| Income Tax Expenses | -153.75M | -164.48M | -173.05M | 1.80M | 1.85M |
| Earnings from Continuing Operations | 314.11 | 298.21 | 287.20 | 77.84 | 60.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 314.11M | 298.21M | 287.20M | 77.84M | 60.64M |
| EBIT | 160.45M | 134.30M | 116.26M | 81.10M | 63.11M |
| EBITDA | 179.83M | 153.71M | 135.71M | 100.55M | 82.58M |
| EPS Basic | 2.38 | 2.26 | 2.16 | 0.58 | 0.44 |
| Normalized Basic EPS | 0.76 | 0.63 | 0.54 | 0.44 | 0.36 |
| EPS Diluted | 2.28 | 2.16 | 2.07 | 0.56 | 0.43 |
| Normalized Diluted EPS | 0.74 | 0.61 | 0.52 | 0.43 | 0.35 |
| Average Basic Shares Outstanding | 526.21M | 531.00M | 537.54M | 547.78M | 559.02M |
| Average Diluted Shares Outstanding | 545.34M | 549.33M | 554.89M | 564.41M | 574.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |